Mirae Asset Global Etfs Holdings Ltd. Crinetics Pharmaceuticals, Inc. Transaction History
Mirae Asset Global Etfs Holdings Ltd.
- $47.1 Billion
- Q2 2025
A detailed history of Mirae Asset Global Etfs Holdings Ltd. transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Mirae Asset Global Etfs Holdings Ltd. holds 53,995 shares of CRNX stock, worth $2.21 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
53,995
Previous 59,311
8.96%
Holding current value
$2.21 Million
Previous $1.99 Million
21.97%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding CRNX
# of Institutions
234Shares Held
90MCall Options Held
59.7KPut Options Held
14.8K-
Vanguard Group Inc Valley Forge, PA9.26MShares$378 Million0.0% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.4MShares$262 Million1.78% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$255 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA5.81MShares$237 Million0.03% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.59MShares$228 Million0.02% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $2.2B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...